Skip to content

Poster: Viral SARS-CoV-2 rebound rates in linked commercial pharmacy-based SARS-CoV-2 RT-qPCR testing and healthcare claims


Viral SARS-CoV-2 rebound has not been well characterized across subpopulations or in large cohorts outside of clinical trials. Uncertainty around rebound has led to the potential under-utilization of nirmatrelvir/ritonavir (NMV-r) treatment.

Key question: What is the rate of viral SARS-CoV-2 rebound in patients treated with NMV-r compared to patients who are not treated?